Xtant Medical (XTNT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Jun, 2026Executive summary
Annual meeting scheduled for August 7, 2026, in New York, with voting available online or in person.
Shareholders are encouraged to review proxy materials and vote by August 6, 2026.
Voting matters and shareholder proposals
Election of six director nominees to serve until the next annual meeting.
Ratification of Grant Thornton LLP as independent auditor for the year ending December 31, 2026.
Advisory (non-binding) vote on executive officer compensation.
Proxies may vote on other business properly brought before the meeting.
Board of directors and corporate governance
Six nominees listed for election to the board: John Bakewell, Jonn Beeson, Sean E. Browne, Abhinav Jain, Tyler P. Lipschultz, and Stavros Vizirgianakis.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Xtant Medical
- Expanded into hemostatic biologics, strengthened balance sheet, and drove innovation for growth.XTNT
Investor presentation - Expanded sales force, new products, and asset sales drive growth and cash generation outlook.XTNT
Canaccord Genuity's 46th Annual Growth Conference - Revenue and margins declined, with a net loss and lower guidance amid supply chain risks.XTNT
Q2 2026 - Strong growth, margin expansion, and strategic acquisitions position the business for continued outperformance.XTNT
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase - Board recommends approval of all proposals, including director elections and executive pay.XTNT
Proxy filing - Raised 2026 revenue guidance to $101M–$105M amid asset sales, new launches, and debt reduction.XTNT
Q1 2026 - Strong 2025 growth, margin expansion, and innovation fuel expansion in orthobiologics and beyond.XTNT
Investor presentation - Q3 2024 revenue up 12% year-over-year; full-year guidance reaffirmed at $116M–$120M.XTNT
Q3 2024 - 2024 revenue up 28% to $117.3M; 2025 guidance $126–$130M, margin and cash flow gains expected.XTNT
Q4 2024